Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Done right, portfolio management is where value originates. Great portfolio managers are able to create and maximize value as fluently as any leading scientist. However, are you confident you and your company are able to define, measure and realize value in early development phases every single time?

Any executive with responsibility for their company’s pipeline will benefit from a new multi-perspective panel discussion we are assembling. Assessment of value has shifted hugely amongst payers, patients and physicians in the past few years and will only accelerate. We’re going to help you better understand how to get real impact from your R&D and Licensing resources. The exclusive panel will help you understand:

• What is the definition for the value we are trying to create? – Witness the different points of view when it comes to defining and assessing value of your compound pipeline according to varying company objectives.
• How can we manage it and measure it? – Improve accuracy on key metrics: attrition rates of compounds in R&D pipelines, number of compounds are in production, productivity, and translation of results into value.
• How can we improve? – Compare traditional methods to a new, broader vision based on qualitative parameters that will give you a clearer conclusion on whether to pursue a produce at preclinical stage